|
Meiragtx Holdings PLC (MGTX) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
MeiraGTx Holdings plc (MGTX) Bundle
Descubra o verdadeiro valor do Meiragtx Holdings plc (MGTX) com nossa calculadora DCF avançada! Ajuste as principais suposições, explore vários cenários e examine como diferentes fatores influenciam a avaliação do Meiragtx Holdings plc (MGTX) - tudo dentro de um modelo abrangente do Excel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 13.3 | 15.6 | 37.7 | 15.9 | 14.0 | 15.7 | 17.5 | 19.6 | 21.9 | 24.5 |
| Revenue Growth, % | 0 | 17.09 | 142.25 | -57.77 | -11.95 | 11.84 | 11.84 | 11.84 | 11.84 | 11.84 |
| EBITDA | -51.4 | -53.7 | -71.4 | -115.9 | -57.1 | -15.7 | -17.5 | -19.6 | -21.9 | -24.5 |
| EBITDA, % | -386.33 | -344.93 | -189.38 | -728.3 | -407.02 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 3.3 | 4.2 | 7.9 | 8.7 | 13.7 | 7.1 | 7.9 | 8.8 | 9.9 | 11.1 |
| Depreciation, % | 25.18 | 26.8 | 20.88 | 54.79 | 97.95 | 45.12 | 45.12 | 45.12 | 45.12 | 45.12 |
| EBIT | -54.7 | -57.9 | -79.3 | -124.7 | -70.8 | -15.7 | -17.5 | -19.6 | -21.9 | -24.5 |
| EBIT, % | -411.51 | -371.73 | -210.27 | -783.1 | -504.97 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 227.2 | 209.5 | 137.7 | 115.5 | 129.6 | 15.7 | 17.5 | 19.6 | 21.9 | 24.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.3 | 38.5 | 35.0 | 29.0 | 23.4 | 15.5 | 17.3 | 19.3 | 21.6 | 24.2 |
| Account Receivables, % | 175.58 | 247.25 | 92.88 | 182.31 | 167.05 | 98.58 | 98.58 | 98.58 | 98.58 | 98.58 |
| Inventories | 4.5 | 7.1 | 8.1 | 8.1 | .0 | 4.8 | 5.3 | 5.9 | 6.7 | 7.4 |
| Inventories, % | 33.58 | 45.5 | 21.49 | 51.09 | 0 | 30.33 | 30.33 | 30.33 | 30.33 | 30.33 |
| Accounts Payable | 3.8 | 7.1 | 15.3 | 16.6 | 16.0 | 9.9 | 11.0 | 12.3 | 13.8 | 15.4 |
| Accounts Payable, % | 28.28 | 45.84 | 40.71 | 104.37 | 114.45 | 62.97 | 62.97 | 62.97 | 62.97 | 62.97 |
| Capital Expenditure | -9.0 | -37.0 | -55.2 | -45.0 | -20.2 | -14.7 | -16.4 | -18.3 | -20.5 | -22.9 |
| Capital Expenditure, % | -67.56 | -237.87 | -146.46 | -282.43 | -143.93 | -93.51 | -93.51 | -93.51 | -93.51 | -93.51 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -52.5 | -53.8 | -71.7 | -137.4 | -70.8 | -15.0 | -16.8 | -18.8 | -21.0 | -23.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -82.2 | -101.1 | -108.4 | -166.4 | -64.1 | -25.6 | -26.5 | -29.7 | -33.2 | -37.1 |
| WACC, % | 10.74 | 10.66 | 10.59 | 10.84 | 10.84 | 10.73 | 10.73 | 10.73 | 10.73 | 10.73 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -110.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -38 | |||||||||
| Terminal Value | -433 | |||||||||
| Present Terminal Value | -260 | |||||||||
| Enterprise Value | -371 | |||||||||
| Net Debt | -40 | |||||||||
| Equity Value | -331 | |||||||||
| Diluted Shares Outstanding, MM | 56 | |||||||||
| Equity Value Per Share | -5.86 |
What You Will Receive
- Pre-Filled Financial Model: MeiraGTx's actual data provides accurate DCF valuation.
- Comprehensive Forecast Control: Modify revenue growth, margins, WACC, and other essential drivers.
- Instantaneous Calculations: Automatic updates allow you to view results in real-time as adjustments are made.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated application for detailed forecasts.
Key Features
- Customizable Financial Inputs: Adjust essential metrics such as research and development expenses, revenue projections, and operational costs.
- Instant DCF Valuation: Automatically computes intrinsic value, net present value (NPV), and additional financial metrics.
- High-Precision Accuracy: Leverages MeiraGTx’s actual financial data for dependable valuation results.
- Effortless Scenario Analysis: Easily evaluate various assumptions and analyze the resulting impacts.
- Efficiency Booster: Streamlines the valuation process, eliminating the need for intricate model construction.
How It Works
- Download: Obtain the pre-configured Excel file containing MeiraGTx Holdings plc's (MGTX) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC to suit your analysis.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time as you make changes.
- Test Scenarios: Develop various forecasts and instantly compare the resulting outcomes.
- Make Decisions: Leverage the valuation findings to inform your investment strategy.
Why Choose This Calculator for MeiraGTx Holdings plc (MGTX)?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses tailored for MGTX.
- Flexible Inputs: Modify the highlighted cells to explore different financial scenarios.
- In-Depth Analysis: Automatically computes MeiraGTx's intrinsic value and Net Present Value.
- Preloaded Information: Access historical and projected data for reliable analysis.
- High-Quality Standards: Perfect for financial analysts, investors, and business advisors focusing on MGTX.
Who Should Use This Product?
- Biotech Students: Explore gene therapy concepts and apply them using real-world data.
- Researchers: Integrate cutting-edge models into studies or academic projects.
- Investors: Evaluate your investment strategies and analyze valuation metrics for MeiraGTx Holdings plc (MGTX).
- Financial Analysts: Enhance your analysis with a customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Understand the market dynamics of publicly traded biotech companies like MeiraGTx Holdings plc (MGTX).
What the Template Contains
- Historical Data: Includes MeiraGTx's past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate MeiraGTx's intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of MeiraGTx's financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.